Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada

Abstract

Introduction: There have been significant advances in systemic therapies for metastatic renal cell carcinoma (mRCC). There are currently 11 drugs approved by Health Canada: sunitinib, sorafenib, pazopanib, axitinib, everolimus, temsirolimus, nivolumab, ipilimumab, cabozantinib, lenvatinib, and pembrolizumab. These novel medications have dramatically altered the prognosis and patient experience. Despite proven benefits and recommendations for funding of most of these drugs, public access has been uneven across Canadian provinces. Methods: We describe the provincial differences and timelines in public funding for approved systemic therapies for mRCC in Canada. Drug funding data was collected from the pan-Canadian Oncology Drug Review (pCODR) database and provincial drug formularies. Missing information was obtained from provincial cancer center pharmacists or drug formulary managers. We compared these dates to data available through regulatory bodies in the U.S., Europe, and Australia. Results: There have been significant differences in the dates of approval for public funding among the provinces, with lags spanning between 17 and 57 months. Funding approval was typically earlier in western provinces and those with denser populations, and most delayed in smaller, eastern provinces. Approval timelines in Canada were similar to those in the U.S., Europe, and Australia. Conclusions: Most drugs approved for use in mRCC are publicly funded for specific patient populations across Canada. However, we illustrate considerable disparities in public funding implementation across the Canadian provinces. These funding lags may create inequities and differences in the patient experience across the Canadian healthcare system.

Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada

“…For example, there was more than a 17-month lag in a positive funding decision for pertuzumab for HER2-positive advanced breast cancer between the first province to offer funding (British Columbia) and the last (Prince Edward Island) [ 30 ]. The existence and impact of these lags in funding have been studied in detail and arguably risks creating a dramatically different patient care experience depending on provincial residency [ 31 , 32 , 33 , 34 ]. Previous research by Gotfrit et al also shows substantial potential total life-years lost (39,067 life-years lost between 2011–2016) experienced by patients due to the lag in time between proof of efficacy until a positive funding decision is made [ 34 ].…”

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action

“…Consequently, patient access to innovative drugs is usually greatly delayed due to the sequential federal and provincial processes in regulatory and reimbursement reviews. Such lengthy timelines, which can vary greatly across provinces and territories [ 6 , 7 , 8 ], may have a significant impact on patients’ survival and quality of life (QoL). This is especially true for cancer patients, in both the metastatic setting (given their reduced or limited life expectancy) and the curative setting (where adjuvant medicines improve the chance of cure) [ 9 , 10 ].…”